Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone

Area of Science:

• Geriatric Psychiatry
• Schizophrenia Treatment
• Pharmacotherapy

Background:

• Determining remission in elderly schizophrenia patients is challenging due to factors like disease duration, treatment history, side effects, adherence issues, cognitive decline, and comorbidities.
• Elderly individuals with schizophrenia often face complex clinical scenarios complicating remission assessment.

Purpose of the Study:

• To evaluate the efficacy of long-acting risperidone (LAR) in achieving symptomatic remission in elderly schizophrenia patients.
• To assess the tolerability and adherence rates associated with LAR treatment in this demographic.

Main Methods:

• Retrospective chart review of 48 elderly (60+ years) schizophrenia patients admitted with symptom exacerbation.
• Utilized the American Psychiatric Association's "Remission in Schizophrenia Working Group" criteria for remission assessment.
• Clinical status and improvement were measured using the Clinical Global Impression (CGI) scale.

Main Results:

• Of 25 patients treated with LAR, 19 (76%) maintained treatment for over 6 months.
• Sixty percent (15/25) of patients achieved symptomatic remission after six months of LAR treatment.
• Significant improvement was observed on the CGI-global improvement scale, with 18 patients rated as "improved" or "very much improved".

Conclusions:

• Long-acting risperidone (LAR) demonstrates potential efficacy in achieving remission in elderly schizophrenia patients.
• LAR treatment was associated with high tolerability and improved patient adherence.
• Findings should be interpreted with caution due to the retrospective nature and inherent biases of the study.